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Abstract
Background and Aims: The aim of this study was to investigate the genome-wide DNA methylation 
status in treatment-naïve ulcerative colitis [UC], and to explore the relationship between DNA 
methylation patterns and gene expression levels in tissue biopsies from a well-stratified treatment-
naïve UC patient group.
Methods: Mucosal biopsies from treatment-naïve patients [n = 10], and a healthy control group 
[n = 11] underwent genome-wide DNA bisulfite sequencing. Principal component analysis [PCA] 
and diverse statistical methods were applied to obtain a dataset of differentially methylated 
genes. DNA methylation annotation was investigated using the UCSC Genome Browser. Gene set 
enrichments were obtained using the Kyoto Encyclopaedia of Genes and Genomes [KEGG] and 
PANTHER.
Results: Of all significantly differentially expressed genes [DEGs], 25% correlated with DNA 
methylation patterns; 30% of these genes were methylated at CpG sites near their transcription 
start site [TSS]. Hyper-methylation was observed for genes involved in homeostasis and defence, 
whereas hypo-methylation was observed for genes playing a role in immune response [i.e. 
chemokines and interleukins]. Of the differentially DNA methylated genes, 25 were identified 
as inflammatory bowel disease [IBD] susceptibility genes. Four genes [DEFFA6, REG1B, BTNL3, 
OLFM4] showed DNA methylation in the absence of known CpG islands.
Conclusions: Genome-wide DNA methylation analysis revealed distinctive functional patterns for 
hyper-and hypo-methylation in treatment-naïve UC. These distinct patterns could be of importance 
in the development and pathogenesis of UC. Further investigation of DNA methylation patterns 
may be useful in the development of the targeting of epigenetic processes, and may allow new 
treatment and target strategies for UC patients.
Keywords:  Genome-wide DNA methylation; ulcerative colitis [UC]
1. Introduction
Ulcerative colitis [UC] is one of the two most common conditions 
that constitute inflammatory bowel disease [IBD] in addition to 
Crohn’s disease [CD]. Whereas CD can affect any area in the gastro-
intestinal tract, UC affects the mucosa and submucosa of the colon 
and rectum.1,2 Due to chronic inflammation, patients affected by UC 
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have a higher risk of developing colorectal cancer.3 Approximately 
20% of IBD cases can be explained by known genetic variants, sug-
gesting a more complex pathogenesis.4–6 The current knowledge of 
the underlying causes of UC is still incomplete. A complex interplay 
between genetic variation, host immune system, environmental fac-
tors and intestinal microbiota has been suggested.4 Therefore, it has 
been implied that epigenetic mechanisms may play an important role 
in disease development of UC.7–11 Epigenetic processes regulate gene 
expression via modifications of DNA, histone proteins and chroma-
tin, and are known to play a role in complex disease phenotypes.12 
Epigenetic modifications, such as DNA methylation, are believed to 
have a role in the immune dysfunction associated with IBD.13 They 
are influenced by several environmental factors such as diet14,15 and 
smoking16 which are known to be associated with inflammatory dis-
eases.17,18 Gene-specific changes in DNA methylation in the patho-
genesis of IBD have been recently reported.19–22 DNA methylation 
plays a regulatory role in gene transcription, either by activation of 
proteins that interfere with the suppression of gene transcription, or 
by inhibiting transcription factors from binding to DNA.23–25 That is 
why it isimportant to examine the interaction between gene expres-
sion and DNA methylation.
Therefore, in the present study we applied genome-wide methy-
lation profiling by using bisulfite sequencing in order to obtain 
DNA methylation patterns at a single base-pair resolution.26,27 This 
method is a more quantitative approach in producing data with 
genome-wide coverage than other technologies.28,29 In addition, 
DNA methylation has been correlated to transcriptional levels of 
genes in order to demonstrate possible regulatory DNA methylation 
features of relevance for UC.
2. Materials and Methods
2.1. Patient material
A standardised sampling method was used to collect mucosal biop-
sies from the colon of newly diagnosed, treatment-naïve UC patients 
with mild to moderate disease activity [n = 10] and controls [n = 11]. 
For controls, biopsies from subjects undergoing cancer screening 
with normal colonoscopy and normal colonic histological examin-
ation were used. UC was diagnosed based upon established clinical, 
endoscopic and histological criteria as defined by the ECCO guide-
lines.30 The grade of inflammation was assessed during colonoscopy 
using the UC disease activity index [UCDAI] endoscopic sub-score, 
with 3 to 10 for mild to moderate disease.31 All biopsies were taken 
from the sigmoid part of the colon and the case biopsies from a 
site of active inflammation. Tumour necrosis factor alpha [TNF-α] 
mRNA expression levels were measured by real-time quantitative 
polymerase chain reaction PCR [qPCR], thereby indicating the grade 
of UC activity.32 This study is part of a larger, already published study, 
where the gene expression using transcriptome data was assessed.33 
The samples were taken from an established biobank approved by 
the Norwegian Board of Health. The participants signed an informed 
and written consent form. The study was approved by the Regional 
Ethics Committee of North Norway and the Norwegian Social Data 
Services [REK Nord 2012/1349].
2.2. DNA and RNA isolation
Genomic DNA was isolated using the Allprep DNA/RNA Mini 
Kit from Qiagen and the QIAcube instrument [Qiagen, Hilden, 
Germany], according to the manufacturer’s protocol. DNA quantity 
and purity were assessed by using the NanoDrop ND-1000 spectro-
photometer [Thermo Fisher Scientific, Wilmington, DE, USA]. The 
DNA samples were kept at -80°C until further handling.
2.3. Quantitative polymerase chain reaction [qPCR]
The TNF-α levels in biopsies were measured using qPCR. RNA 
quantity was assessed with NanoVue Plus [GE Healthcare, UK]. 
Synthesis of cDNA was performed using the QuantiTect Reverse 
Transcription Kit [Qiagen], and the QuantiNova Probe PCR Kit 
[Qiagen, Hilden, Germany]. Beta-actin [β-actin] was used as house-
keeping gene. For the detection, a CFX Connect Real Time PCR 
Detection System [Bio-Rad, USA] was used. The results were meas-
ured in copies/µg protein. Values <7000 copies/µg protein are consid-
ered as non-inflamed tissues, and values >7000 copies/µg protein are 
considered as inflamed tissues.32
2.4. Library preparation and next-generation 
sequencing
DNA libraries were prepared with the SeqCap Epi CpGiant 
Enrichment kit [Roche, Switzerland]. The DNA was bisulfite-
converted using the EZ DNA Methylation-lightning Kit [Zymo 
Research, USA] before the hybridisation step and according to the 
manufacturer’s instructions. Transcriptome libraries were prepared 
as described previously.33 The amount of input material was 1060 ng 
of genomic DNA per sample. The Bioanalyzer 2100 and the Agilent 
DNA 1000 kit [Agilent Technologies, Santa Clara, USA] were used 
to assess the quality of DNA libraries. DNA libraries with an average 
fragment size of 329 bp were generated, then diluted to 2 nM, and 
subsequently sequenced with the NextSeq 550 instrument [Illumina, 
USA] according to the manufacturer’s instructions.
2.5. Data analysis
The algorithm package STAR-2.5.2b [https://github.com/alex-
dobin/STAR] was used for down-stream analysis of the transcrip-
tome.34 Transcripts were aligned to UCSC GRCh38/hg38 [http://
hgdownload.cse.ucsc.edu/goldenPath/hg38/]. The count matrix 
was generated by HTSeq-count [https://htseq.readthedocs.io/en/
release_0.9.1/], normalised by DESeq2 [https://bioconductor.org/
packages/release/bioc/html/DESeq2.html]. Principal component 
analysis [PCA],35 Limma,36 and p-value adjustment methods37 in 
Bioconductor R [https://www.bioconductor.org/] were used to 
obtain and characterise a dataset of significant DEGs and for ana-
lysis of relative methylation in patient samples.
For DNA methylation analyses, the Bismark Bisulfite Mapper 
v0.16.0 [www.bioinformatics.bbsrc.ac.uk/projects/bismark/] was used 
and the same genome build as the transcriptome was used to generate 
methylation counts. The globalTest function from the BiSeq package 
[https://bioconductor.org/packages/release/bioc/html/BiSeq.html] was 
used to find significant differentially methylated regions between UC 
and normal samples. As whole-genome bisulfite sequencing [WGBS] 
data are extremely computationally expensive and rather large, areas 
of interest were reduced to the promoter regions of expressed tran-
scripts [DESeq2] and transcripts whose normalised log2 [counts] were 
greater than 5.  To find differentially methylated regions, Goeman’s 
Global test was used.38,39 A  modified algorithm of the Goemans’s 
Global test in the BiSeq package [https://bioconductor.org/packages/
release/bioc/vignettes/BiSeq/inst/doc/BiSeq.pdf] works with relative 
methylation data and score tests, with methylation levels as independ-
ent variables. Promoters with Goeman’s test p-values < 0.05 were kept 
for further use. Significant regions with low coverage [few methyla-
tion sites] or a poor Goeman’s statistic were removed. Differentially 
methylated regions [DMR] of interest were restricted to 200 bp down-
stream and 2000 bp upstream of a transcription start site [TSS]. DMR 
regions were further restricted to those containing a minimum of four 
methylation events. DMRs were investigated with the UCSC Genome 
Browser [https://genome.ucsc.edu/].
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Genes associated with the risk of IBD were downloaded from 
the genome-wide association studies [GWAS] catalogue,40 using 
the search term IBD [www.ebi.ac.uk/gwas]. Gene set enrichments 
were performed by using the PANTHER classification system 
[https:// pantherdb.org/], the Kyoto Encyclopaedia of Genes and 
Genomes [KEGG; www.genome.jp/kegg/]. For principal compo-
nent analysis [PCA] of the transcription data, the top 5000 most 
variable of the DESeq2-Rlog variance stabilised transcripts were 
used. For the estimation of specific cell populations in patient 
transcription samples, all DESeq2-Rlog normalised transcripts 
with a log2 average mean >5 were included. The analysis was 
performed using the R/Bioconductor CellMix manual [http://
web.cbio.uct.ac.za/~renaud/CRAN/web/CellMix/] with the IRIS 
weighted marker list characteristic for the different cell types41 
and as described previously.33 To investigate the correlation 
between the cell deconvolution PCA and the methylation PCA 
scores, partial least squares regression [PLSR] [https://cran.r-
project.org/web/packages/pls/index.html] was used.42 In order 
to visualise co-variation, the procrustes algorithm [https://www.
rdocumentation.org/packages/vegan/versions/2.4-2/topics/pro-
crustes] was applied.43
Fisher’s exact test44 was used to compare if the gene list 
depicted in Supplementary Data 2 [available as Supplementary 
data at ECCO-JCC online] associated with significant methylation 




Mucosal biopsies from treatment-naïve UC patients [n = 10] and 
controls [n = 11] were collected according to a standardised sam-
pling method, as described in Materials and Methods [section 2]. 
The disease activity within UC patients was classified30 as mild to 
moderate as described by the UCDAI; the biopsies showed clinical 
scores of 7 ± standard deviation [SD] 2.6 and endoscopy scores of 
1.9  ±  SD 0.3. The biopsies from the control group showed nor-
mal colonoscopy, colon histology, and immunohistochemistry, with 
clinical and endoscopy scores = 0. All biopsies were taken from the 
sigmoid part of the colon. Gender distribution within both groups 
was almost identical, with seven males in the UC group, eight males 
in the control group, and three females in each group. The age 
distribution differed between the groups, at 37 ± SD 12 years in 
the UC group, and 52 ± SD 14 years in the control group. TNF-α 
mRNA expression levels were measured by qPCR to estimate the 
inflammatory status of UC.32 TNF-α measurements in UC group 
were estimated as 13,240  ±  SD 6056, and for control group as 
4291 ± SD 1878. A summary of all patient characteristics is listed 
in Table 1.
3.2. Characterisation of DNA methylation in 
treatment-naïve UC
Pre-processing of the initial RNA and bisulfite sequencing data 
revealed expression of about 22 000 transcripts which were used 
for initial principal component analysis [PCA] depicting relative 
methylation counts [0–100%] for over 9 million cytosine positions 
for the whole genome of all patient samples, both treatment-naïve 
UC and normal controls. PCA revealed a clear distinction between 
UC samples and normal control samples along the first component 
with a 13.5% explained variance [Figure 1]. Only one patient sam-
ple could not be distinguished from normal samples by this method 
[Figure  1]. A  PCA plot indicating the age of participants showed 
no evidence for age clustering [Supplementary Data 1, available as 
Supplementary data at ECCO-JCC online].
The whole transcriptome of treatment-naïve UC has been 
recently established, and has been used as a basis for the interpret-
ation of DNA methylation patterns in UC.33 Results show that 25% 
of the significantly DEGs [P-value < 0.05; log2 fold-change > 1.0; 
n  =  357] correlated with the observed differential DNA methyla-
tion, which resulted in 30% hyper-methylated [n  =  87] and 70% 
hypo-methylated [n = 270] genes [Supplementary Data 2]. Further 
analysis revealed that approximately 30% of the genes showed DNA 
methylation at CpG sites in the neighbourhood of their transcription 
start site [TSS], whereas the remaining 70% showed DNA methyla-
tion events at cis-acting elements like DNAse1 and enhancers. The 
relationship between the raw methylation data per sample, average 
difference between groups, and relationship to the TSS and tran-
script expression for all differentially methylated genes is depicted in 
Supplementary Data 3 [available as Supplementary data at ECCO-
JCC online].
Of the differentially methylated genes, 25 have been related 
to the currently known 295 IBD susceptibility genes, of which 23 
were hypo-methylated and two were hyper-methylated, and corre-
lated with their direction of transcription [Table 2]. Gene annotation 
revealed their involvement in pathways for cell adhesion, intracellular 
Table 1. Patient characteristics.
Characteristics Control group  
[n = 11]
Ulcerative colitis  
[n = 10]
Male/female 8/3 7/3
Age mean ± SD 52 ± 14 37 ± 12
Endo score mean ± SD 0 1.9 ± 0.3
Clinical score ± SD 0 7 ± 2.6
TNF-α level ± SD 4291 ± 1878 13,240 ± 6056
SD, standard deviation; TNF, tumour necrosis factor.
























Figure  1. Unsupervised principal component analysis [PCA] depicting 
relative methylation counts [0–100%] for over nine M cytosine positions, 
including treatment-naïve ulcerative colitis [UC] [red; n  =  10] and normal 
control [blue; n = 11] patient tissue samples with a variance of 13.5%.
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signalling, metabolism, and transport. For six of the IBD suscepti-
bility genes, neutrophil-activating protein 78 [CXCL5], fatty acid 
desaturase 1 [FADS1], intercellular adhesion molecule 1 [ICAM], sol-
ute carrier family 22 member 4 [SLC22A4], tumour necrosis factor 
receptor superfamily, member 5 [CD40; TNFRSF5], and TNF recep-
tor superfamily member 4 [TNFRSF4] DNA methylation occurred at 
the transcription start site [TSS] and as indicated in Table 2.47,48
The most down-regulated [P  <  0.05 and log2FC  >  1.5] and 
hyper-methylated genes in treatment-naïve UC are depicted in 
Table  3. Annotations revealed genes with the most possible rele-
vance for UC: six members of the solute carrier family [SLC17A8, 
SLC22A4, SLC25A34, SLC30A10, SLC3A1, and SLC6A19], two 
guanylate cyclase activators [GUCA2A and GUCA2B], defensin 
B1 [DEFB1], intestinal alkaline phosphatase 1 [ALPI], two UDP-
glucuronosyltransferases [UGTA8 and UGTA10], bone morpho-
genic protein/retinoic acid inducible neural-specific 3 [BRNP3], and 
proline rich acidic protein [PRAP1].
Hypo-methylated genes in treatment-naïve UC are listed in 
Table 4. DEGs with log2FC > 3.0 and P < 0.05 and their correspond-
ing methylation status have been included in the list. The annotation 
of the hypo-methylated transcripts revealed genes involved in inflam-
matory responses, like chemokine receptors [CXCR1, CXCR2], 
chemokine ligands [CXCL5, CXCL6], interleukins [IL 17A, IL1B], 
defensins [REG3A, DEFA6], and genes involved in cytokine signal-
ling [SAA1, SAA2, LCN2]. Other hypo-methylations relevant for 
UC are observed for transporters like aquaporin 9 [AQP9], mem-
bers of the solute carrier family [SLC6A4, SLC6A14], oncostatin 
[OSM], and olfactomedin [OLFM4]. For four genes, the observed 
DNA methylation occurred in the absence of CpG islands or other 
well-known cis-acting regulatory domains; these genes are defensin 
A6 [DEFA6], olfactomedin 4 [OLFM4], regenerating protein beta 
1 [REG1B], and butyrophilin like protein3 [BTNL3], as shown in 
Figure 2 and Table 5.
In order to explain if cell type populations in biopsies can 
explain some of the variation in DNA methylation profiles, previ-
ously reported cellndeconvolution results of the transcriptome33 
and DNA methylation data were patient-matched and underwent 
PCA analysis. Further, partial least squares regression [PLSR]42 
between the cell deconvolution PCA and the methylation PCA scores 
showed a strong correlation [Supplementary Data 4, available as 
Supplementary data at ECCO-JCC online].
To visualise co-variation between cell type contributions to 
methylation data, a biplot of the initial deconvolution PCA for the 
transcriptome was used in order to display information on both 
samples and variables [cell types] of the PCA result graphically. 
The procrustes algorithm43 was then used to overlay the methy-
lation PCA sample scores onto the cell deconvolution biplot. The 
result shows that cell type is a significant determinant in methylation 
profile [Supplementary Data 5, available as Supplementary data at 
ECCO-JCC online].
Table 2. DNA methylated inflammatory bowel disease [IBD] susceptibility genes in treatment-naïve ulcerative colitis [UC].
Gene symbol & annotation % methyl methyl  
methylation
p < 0.05 #c p < 0.05 Log2 fc > 1.0
[log2fc > 1.0; p < 0.5]
Cell adhesion & intercellular signalling methyl
met me
transcript transcript
CD40a 6,81 0,0426 94 1,12E-20  1,64
CXCL5a 19,21 1,38E-05 30 7,17E-20  4,62
CXCL6 10,20 0,0041 18 5,46E-26  4,06
CXCR5 16,18 0,0004 36 1,36E-07  2,06
FCGR3A 2,69 0,0036 30 2,02E-20  2,13
ICAM1a 2,65 0,0034 18 6,61E-28  1,96
IFNG 8,55 0,0057 10 1,54E-06  1,54
IL12RB2 1,97 0,0035 39 7,15E-10  1,03
IL2RA 25,53 0,0001 24 2,51E-17  2,45
ITGAL 15,90 0,0002 10 2,64E-12  1,29
OSM 22,59 0,0002 36 2.00E-17  3,09
SLAMF1 26,79 3,12E-06 11 1,72E-11  1,34
SLAMF7 11,29 0,0062 7 1,11E-07  1,04
TNFRSF9 0,40 0,0075 6 5,27E-24  2,91
TNFRSF4a 3,65 0,0348 76 3,46E-18  1,73
TNFSF8 28,03 0,0002 23 1,71E-06  1,01
Intracellular signalling
APOBEC3G 36,88 0,0241 55 1,68E-15  1,35
CCDC88B 17,29 5,89E-06 118 1,18E-23  1,95
CD6 19,40 3,13E-05 48 2,34E-10  1,44
DOK3 10,80 0,0082 30 5,03E-22  1,77
UBASH3A 5,39 0,0381 8 1,29E-06  1,05
Metabolism
ARHGAP30 36,89 2,22E-07 17 1,19E-12  1,13
FADS1a 0,18 0,0141 30 7,93E-12  1,30
SULT1A2 -8,85 0,0089 13 7,56E-09 -1,67
Transport
SLC22A4a -0,37 0,0092 172 1,24E-27 -1,72
#c indicates number of methylated cytosines; % methyl indicates % difference of DNA methylation normal [N]-UC.
aCpG sites at their transcription start site [TSS].
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Comparison of methylated genes [Supplementary data 2] showed 
significant overlaps with previous comparisons between methy-
lation status peripheral blood mononuclear cells [PBMCs] from 
UC cases and controls,45 intestinal biopsies from controls and UC 
patients,46 and rectal biopsies22 [Supplementary Data 6, available as 
Supplementary data at ECCO-JCC online].
4. Discussion
It is generally accepted that epigenetic mechanisms like DNA methy-
lation are contributing factors in the pathogenesis of IBD.13,45 The 
present study is the first comprehensive study giving a truly genome-
wide description of DNA methylation of treatment-naïve UC using 
next-generation sequencing [NGS]-based bisulfite-sequencing. 
Furthermore, this study provides an interpretation of DNA methyla-
tion status in treatment-naïve UC with correlation to transcriptional 
levels of genes.33
Genome-wide DNA methylation changes in UC have been 
usually investigated by applying microarray technologies.19,45,49,50 
A  correlation between DNA methylation and gene transcription 
has not been established, except for two recent publication where 
a few gene candidates have been confirmed by pyro-sequencing.22,46 
However, the evaluated degree of overlap between the present gene 
list [Supplementary Data  2] and previous genome-wide analyses 
of methylation using microarray-based technologies22,45,46 is much 
larger than those expected by chance [Supplementary Data 6, avail-
able as Supplementary data at ECCO-JCC online]. The use of 
microarray technology has several limitations, one of which is that 
attached array oligo probes might include single nucleotide poly-
morphisms [SNPs] or repetitive elements which can affect the out-
come of the methylation analysis.19 In addition, pre-defined oligo 
probes do not cover all regions in the genome where methylation 
could occur,28,29 leaving possible methylation events undetected and/
or resulting in compromised DNA methylation patterns. This may 
be the reason for contradictory results regarding the DNA methy-
lation of neutrophil-activating peptide 78 [CXCL5] in UC, where 
hyper-methylation has been recently reported which is in contrast to 
the hypo-methylation observed in this study.20 All these limitations 
are bypassed with next-generation sequencing technology where 
methylation detection occurs at a single base-pair, thereby providing 
methylation profiles with full nucleotide level resolution.26
The use of a thoroughly stratified patient group representing 
only treatment-naïve UC for DNA methylation analysis offered a 
unique opportunity to investigate the DNA methylation state before 
Table 3. TOP down-regulated and hyper-methylated genes in treatment-naïve ulcerative colitis [UC]
Gene symbol % methyl p < 0.05 #c p < 0.05 Log2fc > 1.5
methyl transcript transcript
ADIRF -5,72 0,004 36  4,34E-18 -1,88
AGMO -10,86 0,022 7 9,44E-09 -1,57
ALPI -3,05 0,0102 34 1,10E-14 -1,91
ANKRD62 -0,19 0,0011 91  2,47E-14 -2,25
BCHE -4,17 0,0442 10  4,86E-12 -1,69
BRINP3 -0,22 0,0407 29  6,76E-11 -1,74
CLDN8 -0,45 0,0005 8  2,17E-05 -1,9
CYP3A4 -15,45 0,0009 2  3,87E-21 -3,58
DEFB1 -7,09 0,0334 16  2,16E-11 -1,94
FABP1 -16,56 1,52E-05 18 1,36E-07 -1,66
FAM151A -3,59 0,0091 16  4,28E-12 -1,59
FRMD1 -2,58 0,0076 109  4,49E-14 -2,26
GBA3 -14,5 0,0033 7  1,15E-07 -1,98
GUCA2A -12,84 0,0134 18  8,25E-10 -2,26
GUCA2B -3,08 0,0345 41  2,67E-08 -2,18
HAVCR1 -12,55 3,60E-05 6  4,58E-12 -2,28
HMGCS2 -13,13 6,56E-05 18  2,91E-08 -2,41
HSD17B2 -2,69 0,0456 15  1,71E-23 -2,11
MEP1A -11,49 0,009 18  1,76E-16 -2,15
OTC -6,32 0,0359 28  7,09E-10 -1,68
PCK1 -6,73 0,0212 18  1,52E-07 -2,18
PNLIPRP2 -15,2 5,99E-05 23  1,63E-05 -1,74
PRAP1 -1,32 0,0025 260  1,97E-09 -2,49
SLC17A8 -2,89 0,0082 45 2,95E-06 -1,6
SLC22A4 -0,35 0,0174 172  1,25E-27 -1,72
SLC25A34 -12,01 0,0099 40  2,17E-15 -1,76
SLC30A10 -7,67 0,0006 14  4,89E-10 -1,89
SLC3A1 -15.79 0,0002 10  1,29E-17 -2,43
SLC6A19 -12,17 0,0057 68  1,53E-09 -2,82
SULT1A2 -11,71 0,003 13  7,56E-09 -1,67
TINCR -0,66 0,0107 72  1,58E-12 -1,98
TMIGD1 -9,19 0,0135 6  1,16E-09 -2,32
UGT1A10 -8,16 0,0005 34  4,04E-15 -1,79
UGT1A8 -5,96 0,0091 23  1,67E-10 -1,85
#c indicates number of methylated cytosines. % methyl indicates % difference of DNA methylation normal [N]-UC.
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prescription of any medication. This is of importance, since recent 
reports implied that medication, such as various non-prescription, 
over-the-counter non-steroidal anti-inflammatory drugs [NSAIDs] 
and immunosuppressive drugs can have short- and long-term effects 
on the immune response.51 For example, aspirin has been shown 
to result in hypo-methylation of cadherin 1 [CDH1] in the gas-
tric mucosa.52 In addition, immunosuppressant therapy and long-
standing disease might inaugurate unwanted bias in experiments 
aiming to investigate the treatment-naïve status of UC.53–55 In add-
ition, age may affect DNA methylation.56,57 However, the results 
from the patient population of this study indicated that age does not 
seem to play a significant role [Supplementary Data 1, available as 
Supplementary data at ECCO-JCC online]. This might be due to the 
small number of patients aged over 60 in both control and patient 
groups.
Many studies have characterised DNA methylation in UC with-
out relating the obtained data to transcriptional levels of genes.19,20,22 
The correlation of DNA methylation status with transcription levels 
of genes are of importance in order to define physiological implica-
tions of the DNA methylation event. We have previously character-
ised the whole transcriptome of treatment-naïve UC and used these 
data in order to relate DNA methylation to gene expression.33 The 
results revealed that only 72% of DNA methylation events corres-
pond with differential gene transcription levels [see Supplementary 
Data 2]. Annotations of DNA methylation sites covered regions of 
2000 bp upstream and 200 bp downstream of the transcription start 
site [TSS] of genes, and were found to be correlated with transcrip-
tion levels, thereby revealing possible disease-specific methylation 
patterns. It is noted that CpG islands are associated with the control 
of gene expression, and it would be expected that CpG islands might 
display tissue-specific patterns of DNA methylation.23,58,59 However, 
it has been shown that CpG islands associated with TSS rarely show 
tissue specific methylation patterns24,25,60–62 Instead, CpG regions 
located as far as 2  kb from CpG islands have highly conserved 
patterns of tissue-specific methylation, and methylation is highly 
correlated with reduced gene expression.63 Taking this into consider-
ation, our data revealed 90 genes containing CpG sites in this region 
whereof 58 were at the transcription start site [TSS] of genes; 34 
genes showed DNA methylation upstream TSS and might be con-
sidered as tissue-specific DNA methylation sites [Supplementary 
Data  3]. A  number of hyper-methylations with corresponding 
gene expression levels have been found in this study [Table 3]. For 
example, bone morphogenic/retinoic acid inducible neural-specific 
protein 3 [BRINP3] has been reported to be usually under-expressed 
in UC.64 BRINP3 expression is influenced by DNA hyper-methyla-
tion within its promoter, as has been reported recently.65
Cell type populations present in tissue biopsies might also 
explain some of the variation observed in DNA methylation pro-
files [Supplementary Data 4 and  5]. During inflammation of the 
mucosa, the fraction of epithelial cells is diminished, which results 
in impaired intestinal permeability and a dysregulation of homeo-
stasis.66,67 This might be reflected by the hyper-methylation and 
Table 4. TOP up-regulated and hypo-methylated genes in treatment-naïve ulcerative colitis [UC].
Gene symbol % methyl p < 0.05 methyl #c p < 0.05
transcript
Log2 fc > 3.0  
transcript
AQ9 6,39 0,0013 17 3,562E-32 5,37
C2CD4A 2,43 0,0007 64 1,99E-35 3,72
CD300E 13,58 0,0036 11 4,45E-22 3,44
CHI3L2 11,96 6,26E-06 38 8,53E-17 3,32
CHRDL2 10,62 0,0403 65 5,82E-20 3,34
CXCL5  18,85 1,20E-05 30 7,17E-20 4,63
CXCL6 11,03 0,0020 18 5,46E-26 4,06
CXCR1 6,08 0,0013 6 3,92E-23 4,64
CXCR2 6,03 0,0159 20 2,37E-17 3,44
DEFA6 10,44 0,0002 12 1,74E-15 3,75
DMBT1 11,24 5,84E-06 16 4,19E-17 3,49
FCN1 8,55 0,0459 12 3,57E-28 3,25
FFAR2 2,16 9,25E-05 54 1,91E-20 3,02
GABRP 7,43 0,0257 16 8,36E-35 3,72
GZMB 12,88 0,0005 6 3,37E-24 3,16
HCAR2 9,48 0,0012 26 8,69E-22 3,58
HCAR3 14,16 0,0010 18 5,01E-22 4,32
IL17A 9,08 7,82E-06 32 1,50E-33 5,03
IL1B 9,15 2,73E-08 13 1,09E-32 3,28
LCN2 5,23 0,0243 29 2,24E-53 4,95
LYPD5 3,93 0,0254 40 5,55E-23 3,07
OLFM4 10,75 0,0251 24 1,02E-13 3,49
OSM 22,21 0,0008 36 2,01E-17 3,10
PI3 2,26 0,0153 14 2,73E-31 4,11
REG1B 6,63 0,0283 7 3,76E-12 3,73
REG3A 13,27 0,0299 2 2,63E-15 4,19
S100A9 8,26 0,0002 40 1,00E-17 3,46
SAA1 10,55 5,19E-06 26 5,16E-46 6,40
SAA2 11,89 0,0075 6 7,31E-43 6,23
SLC26A4 5,22 8,27E-07 54 3,26E-15 3,28
SLC6A14 3,99 0,0432 29 1,73E-48 5,66
#c indicates number of methylated cytosines. % methyl indicates % difference of DNA methylation normal [N]-UC..
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Figure 2. Genes with novel DNA methylation features in treatment-naïve ulcerative colitis [UC]. The left side of individual illustrations shows the difference in 
relative methylation level between UC and normal samples [N]. Transcription start site [TSS] is indicated as a vertical line. The horizontal line shows where UC 
methylation equals N methylation. Each black circle represents a methylation event. Black circles over the horizontal line represent an increase in UC sample 
methylation compared with N methylation at that site. Black circles under the horizontal line represent an increase in N sample methylation compared with UC 
methylation at that site. The region between 2000 bp upstream and 200 bp downstream of the TSS is shown. The right side of individual illustrations shows 
boxplots of DESEQ2 log2 normalised values for gene of interest, normal control [N] versus ulcerative colitis [UC]. Genes are indicated: defensin A6 [DEFA6]; 
olfactomedin 4 [OLFM4]; butyrophilin like 3 [BTNL3]; regenerating protein 1B [REG1B].
Table 5. Genes with novel DNA methylation features.
Gene symbol % methyl p < 0.05 methyl #c p < 0.05 transcript log2 FC > 1.0 transcript
BTNL3 -13,20 0.0012 16 4,97E-07 -1.31
DEFA6  9,20 0.0002 12 4,56E-17 +3.75
OLFM4  9,95 0.0251 24 3,83E-15 +3.49
REG1B  6,68 0.0282 7 1,95E-13 +3.73
#c indicates number of methylated cytosines. % methyl indicates % difference of DNA methylation normal-ulcerative colitis [N-UC].
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down-regulation of proline-rich acidic protein 1 [PRAP1] and mem-
bers of the solute carrier protein family [SLC6A19 and SLC3A1] 
which are involved in the maintenance of homeostasis in epithe-
lial cells.68–70 In concordance, hyper-methylation of genes that are 
involved in the gut mucosal defence system could also be detected, 
such as intestinal alkaline phosphatase 1 [ALPI] which is involved in 
the prevention of bacterial translocation in the gut,71 and defensin 
B1 [DEFB1] which is predominately expressed in neutrophils and 
is implicated in the resistance of epithelial surfaces to microbial col-
onisation.72 Members of the UDP glucuronosyltransferase family 
[UGT1A10 and UGT1A8] are located primarily in gastrointestinal 
[GI] mucosa from the duodenum to through the colon,73–75 and are 
involved in detoxification in order to restrict GI absorption of dam-
aging chemicals via the cytochrome P450 system [CYP3A4]; all are 
hyper-methylated in UC [Table 3]. In addition, the reported down-
regulation of guanylate cyclase activators GUCA2A and GUCA2B, 
which are involved in gastrointestinal fluid and electrolyte balance, 
is most likely linked to the hyper-methylation of both genes during 
inflammation observed here.76
On the other hand, hypo-methylation with corresponding up-
regulation of genes relevant in UC has been observed. This include 
genes that are up-regulated due to the response to inflammation, and 
represent mostly genes with association to the innate immune system 
like chemokines, chemokine receptors, cytokines, interleukins, and 
transporters [Table 4].33
For further characterisation, the differentially methylated genes 
were related to currently known IBD susceptibility genes, as revealed 
by genome-wide association studies [GWAS].47,48 Of the significantly 
differentially DNA methylated genes, 25 are associated with IBD, 
[Table 2] of which six genes have CpG islands located at their tran-
scription start site [TSS].
The majority of DNA methylation occurs on cytosines that 
precede a guanine nucleotide or CpG sites. However, this study 
reveals previously unknown DNA methylation patterns of genes 
in treatment-naïve UC, which are not dependent on CpG sites or 
known regulatory transcriptional cis-acting elements like DNAse1 
and enhancers. This has been also reported in the tissue of adult 
mouse brain, where a significant percentage of methylated non-CpG 
sites have been identified.77 This phenomenon implies novel regu-
latory features of DNA methylation in UC, with genes involved in 
pro-inflammatory responses and possible antimicrobial activities. 
These would involve defensin A6 [DEFA6] and regenerating protein 
1B [REG1B], facilitation of cell adhesion through interaction with 
lectins and cadherins (olfactomedin 4 [OLFM4]), and lipid metab-
olism (butyrophilin-like 3 [BTLN3]) [Figure  2 and Table  5].78 All 
four genes have been associated with colorectal cancer [CRC] and/or 
have shown to play a role in CRC progression and development.79–83 
However, the role of non-CpG methylation is still unclear.
Regarding the heterogeneity of tissues, it is clear that the methyla-
tion events could occur in different cell subtypes present in the tissue 
samples from UC patients. This might be the situation for DEFA6, 
which is a Paneth cell-specific protein and which is predominantly 
abundant in the epithelia of the intestinal mucosal surface and in 
the granules of neutrophils.84 Epithelial cells are impaired and less 
abundant in the inflamed mucosa,66 and it is therefore believed that 
the observed hypo-methylation of DEFA6 most likely occurs in the 
neutrophils with elevated fractions in inflamed mucosal tissue.85 The 
same might be the situation for BTNL3 which modulates T-cell medi-
ated immune response. The observed hyper-methylation of BTLN3 
may take place in the increased fractions of T lymphocytes present in 
inflamed mucosa. However, with isolated cell fractions or single cell 
sequencing approaches, one would be able to confirm these results.
In conclusion, this comprehensive study shows for the first time 
that the use of well-stratified treatment- naïve UC patient samples in 
combination with genome-wide bisulfite-sequencing technology can 
reveal DNA methylation patterns of importance for UC pathogen-
esis. Potentially significant might be the differential DNA methyla-
tion patterns, with observed hyper-methylation of genes involved in 
homeostasis and defence, and hypo-methylation of genes involved in 
immune response with representative members of the innate immune 
system. Further investigation of such players may be useful for the 
development of epigenetic drugs and may allow new treatment strat-
egies for UC patients in the future.
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